Phio Pharmaceuticals 8-K on results for quarter ended Sept 30, 2025

Phio Pharmaceuticals Corp. filed an 8-K announcing it reported financial results for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Phio Pharmaceuticals Corp. filed an 8-K announcing it reported financial results for the quarter ended September 30, 2025. The company furnished a related press release as Exhibit 99.1.

The disclosure under Item 2.02 is furnished, not filed, and will only be incorporated by reference into other filings if expressly stated. PHIO’s common stock trades on The Nasdaq Capital Market.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PHIO (Phio Pharmaceuticals) announce in this 8-K?

The company reported its financial results for the quarter ended September 30, 2025 and furnished a press release as Exhibit 99.1.

Which 8-K item applies to PHIO’s disclosure?

The results are provided under Item 2.02 — Results of Operations and Financial Condition.

Is the information considered filed or furnished?

The Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not subject to Section 18 liability.

When was the report dated?

The report is dated November 13, 2025.

Where does PHIO’s common stock trade?

PHIO trades on The Nasdaq Capital Market under the symbol PHIO.

What exhibits accompany the 8-K?

The filing includes Exhibit 99.1 (press release) and Exhibit 104 (cover page Inline XBRL).

Will the press release be incorporated into other filings?

It will be incorporated by reference only if a future filing expressly states so.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 04:20 PM EST Learn about SEC filing dates

false 0001533040 0001533040 2025-11-13 2025-11-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 13, 2025

PHIO PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)

Delaware	001-36304	45-3215903
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

411 Swedeland Road, Suite 23-1080
King of Prussia, PA	19406
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (610) 947-0251

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s):		Name of each exchange on which registered:
Common Stock, par value $0.0001 per share		PHIO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2025, Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).

The information in this Item 2.02 and attached as Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by the Company on November 13, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PHIO PHARMACEUTICALS CORP.
Date: November 13, 2025	By:	/s/ Robert J. Bitterman
		Robert J. Bitterman President & Chief Executive Officer

3